查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822372

2032 年麻疹、流行性腮腺炎和德國德國麻疹疫苗市場預測：按產品、疫苗類型、接種途徑、年齡層、通路、最終用戶和地區進行的全球分析

Measles, Mumps, Rubella Vaccines Market Forecasts to 2032 - Global Analysis By Product, Vaccine Type, Route of Administration, Age Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球麻疹、流行性腮腺炎和德國德國麻疹(MMR) 疫苗市場預計在 2025 年達到 57.3 億美元，到 2032 年將達到 138.3 億美元，預測期內的複合年成長率為 13.4%。

麻疹-流行性腮腺炎-德國德國麻疹(MMR) 疫苗是一種聯合疫苗，可保護個人免受三種嚴重感染疾病：麻疹、流行性腮腺炎和德國德國麻疹。透過活化免疫反應，該疫苗可幫助人體抵抗這些病毒，並降低嚴重併發症的風險，包括腦腫脹、呼吸道感染疾病和出生缺陷。 MMR 疫苗主要在兒童時期接種，是公共衛生的基石，有助於實現群體免疫並防止疾病在世界各地傳播。

根據世界衛生組織預測，2023年全球麻疹病例預計將比前一年激增79%以上，通報病例將超過30.6萬例，而人們對疫苗的猶豫日益加劇，使情況更加惡化。

提高對疫苗可預防疾病的認知

各國政府和非政府組織正在利用數位平台和社區計畫推廣免疫接種計畫。行動醫療應用程式與人工智慧提醒系統的整合，正在提高不同族群的疫苗接種依從性。透過實證訊息通訊來反駁錯誤訊息，正在增強家長對常規免疫接種的信心。在新興國家，國際資助的學校免疫接種活動正在蓬勃發展。這種認知度的提升與兒童和成人族群中麻腮風（MMR）疫苗接種率的提高直接相關。

副作用和安全問題

媒體對罕見不利事件的誇大報道，導致某些地區出現疫苗接種猶豫。監管機構正在加強藥物安全檢測通訊協定，並強制要求透過數位醫療記錄進行即時安全監控。製造商正在投資改進配方，以降低反應原性並提高耐受性。社群媒體平台上日益高漲的反疫苗情緒促使相關內容監管更加嚴格，並進行了有針對性的反疫苗宣傳活動。這些與安全相關的擔憂可能會減緩敏感人群的市場擴張。

加強疫苗接種需求不斷增加

隨著免疫力逐漸減弱，麻腮風（MMR）加強針在青少年和成年人中越來越受歡迎。衛生部門正在修訂疫苗接種指南，將定期加強劑納入其中，尤其是在流行地區。疫苗接種技術的進步，例如微針貼片和鼻內製劑，正在改善患者的體驗和依從性。雇主和大學越來越強制要求接種疫苗，這帶來了新的機構需求。數位健康平台正在實現個人化的疫苗追蹤和後續注射的自動安排。這種不斷變化的情況為製造商擴展產品系列和分銷網路提供了機會。

來自替代疫苗的競爭

重組疫苗和基於mRNA的製劑的創新因其更高的功效和更快的生產週期而日益受到關注。一些地區正在採用個人化免疫策略，優先考慮針對特異性疾病的疫苗而非頻譜疫苗。生物技術公司與公共衛生機構之間的策略夥伴關係正在加速下一代疫苗的開發。隨著低溫運輸物流的改進，以前難以取得的疫苗正進入主流分銷管道。如果沒有持續的創新和差異化，傳統的MMR疫苗可能會被這些新興競爭對手搶走市場佔有率。

COVID-19的影響

封鎖和醫療資源的重新分配推遲了小兒科諮詢和疫苗接種。然而，這場危機凸顯了免疫接種的重要性，並促使對疫苗基礎設施進行新的投資。各國政府實施了補種宣傳活動和數位追蹤系統以迎頭趕上。在行動受限的情況下，遠端醫療平台和行動診所已成為推廣的重要工具。後疫情時代策略如今強調韌性供應鏈、分散式交付模式以及將麻腮風（MMR）疫苗納入更廣泛的疫情防範框架。

預測期內，聯合疫苗市場預計將成為最大的市場

聯合疫苗因其便利性和廣泛的保護效力，預計將在預測期內佔據最大的市場佔有率。這些劑型減少了所需的注射次數，並提高了兒童及其看護者的依從性。抗原穩定性和佐劑系統的技術改進提高了免疫抗原性。小兒科更傾向於聯合疫苗，因為它可以提高臨床工作流程的效率並減少預約次數。新型多抗原聯合疫苗的監管核准正在擴大該領域的覆蓋範圍。隨著醫療保健系統優先考慮整合免疫接種計劃，聯合疫苗有望保持主導地位。

預計預測期內小兒科診所部門的複合年成長率最高。

預計小兒科診所細分市場將在預測期內達到最高成長率。這些機構正擴大採用數位免疫記錄和自動化排程系統。出生率的上升和基層醫療可近性的改善推動了小兒科就診量的成長。診所正在採用行動推廣和社區參與模式，以涵蓋服務匱乏的人群。基於人工智慧的診斷工具的整合正在增強早期發現和及時接種疫苗的能力。隨著對預防性醫療保健的日益重視，小兒科診所正成為免疫生態系統的核心節點。

比最大的地區

受醫療基礎設施擴張和人口密度上升的推動，亞太地區預計將在預測期內佔據最大市場佔有率。印度、中國和印尼等國家正在國際支持下擴大國家疫苗接種計畫。行動醫療單位和數位化登記正在改善偏遠地區的疫苗接種途徑。地方政府正在投資本地生產，以減少對進口的依賴。官民合作關係正在加速低溫運輸發展和「最後一哩路」配送。

複合年成長率最高的地區：

在預測期內，受技術創新和積極主動的醫療政策推動，北美預計將呈現最高的複合年成長率。美國和加拿大正在將人工智慧和物聯網融入其疫苗分發和監控系統。監管機構正在簡化先進製劑和給藥機制的核准。遠端醫療平台正在將疫苗分發範圍擴大到傳統診所之外。高昂的公共醫療成本和保險覆蓋率正在推動疫苗的廣泛應用。隨著個人化疫苗接種策略的興起，北美正成為全球疫苗推廣的標竿。

免費客製化服務：

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球麻疹、流行性腮腺炎和德國麻疹(MMR) 疫苗市場（依產品）

  • MMR II
  • PRIORIX
  • Tresivac
  • MM-RvaxPro
  • 其他產品

6. 全球麻疹、流行性腮腺炎和德國麻疹(MMR) 疫苗市場（依疫苗類型）

  • 單一疫苗
  • 聯合疫苗

7. 全球麻疹、流行性腮腺炎和德國麻疹(MMR) 疫苗市場（依接種途徑）

  • 皮下注射
  • 肌肉注射

8. 全球麻疹、流行性腮腺炎和德國德國麻疹(MMR) 疫苗市場（依年齡層）

  • 嬰兒（0-1歲）
  • 兒童（1至12歲）
  • 青年
  • 成人

9. 全球麻疹、流行性腮腺炎和德國麻疹(MMR) 疫苗市場依通路分類

  • 醫院藥房
  • 政府供應商
  • 零售藥局
  • 非政府組織和國際援助項目

10. 全球麻疹、流行性腮腺炎和德國德國麻疹(MMR) 疫苗市場（依最終用戶）

  • 醫院
  • 公共衛生機構
  • 兒科診所
  • 其他最終用戶

11. 全球麻疹-流行性腮腺炎-德國麻疹（MMR）疫苗市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • Merck & Co., Inc.
  • Indian Immunologicals Ltd.
  • GlaxoSmithKline plc（GSK）
  • Meiji Seika Pharma Co., Ltd.
  • Sanofi
  • Panacea Biotec Ltd.
  • Serum Institute of India Pvt. Ltd.
  • LG Chem Ltd.
  • Bharat Biotech International Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Zydus Lifesciences Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Bio-Med Pvt. Ltd.
  • IDT Biologika GmbH
  • Sinovac Biotech Ltd.
Product Code: SMRC31126

According to Stratistics MRC, the Global Measles, Mumps, Rubella (MMR) Vaccines Market is accounted for $5.73 billion in 2025 and is expected to reach $13.83 billion by 2032 growing at a CAGR of 13.4% during the forecast period. The Measles, Mumps, Rubella (MMR) vaccine is a combined immunization that shields individuals from three serious infectious diseases: measles, mumps, and rubella. By activating the immune response, it equips the body to resist these viruses, reducing risks of severe complications like brain swelling, respiratory infections, and birth defects. Administered primarily in childhood, MMR vaccination is a cornerstone of public health, helping achieve herd immunity and preventing widespread disease transmission worldwide.

According to WHO, measles cases surged by over 79% globally in 2023 compared to the previous year, with over 306,000 reported cases and a growing trend in vaccine hesitancy worsening the situation.

Market Dynamics:

Driver:

Increasing awareness about vaccine-preventable diseases

Governments and NGOs are leveraging digital platforms and community-based programs to promote immunization schedules. The integration of mobile health apps and AI-driven reminders is improving vaccine compliance across diverse populations. As misinformation is countered with evidence-based messaging, parental confidence in routine immunizations is rising. Emerging economies are witnessing a surge in school-based vaccination drives, supported by international funding. This growing consciousness is directly translating into higher uptake of MMR vaccines across both pediatric and adult cohorts.

Restraint:

Adverse effects and safety concerns

Media amplification of rare adverse events has led to vaccine hesitancy in certain regions. Regulatory bodies are tightening pharmacovigilance protocols and mandating real-time safety monitoring through digital health records. Manufacturers are investing in formulation improvements to reduce reactogenicity and enhance tolerability. The rise of anti-vaccine sentiment on social media platforms is prompting stricter content moderation and targeted counter-campaigns. These safety-related apprehensions may slow market expansion in sensitive demographics.

Opportunity:

Rising demand for booster immunizations

As immunity wanes over time, booster doses for MMR are gaining traction among adolescents and adults. Health authorities are revising immunization guidelines to include periodic boosters, especially in outbreak-prone zones. Technological advancements in vaccine delivery-such as microneedle patches and intranasal formulations-are improving patient experience and compliance. Employers and universities are increasingly mandating booster shots, creating new institutional demand. Digital health platforms are enabling personalized vaccine tracking and automated scheduling for follow-up doses. This evolving landscape presents a lucrative opportunity for manufacturers to expand product portfolios and distribution networks.

Threat:

Competition from alternative vaccines

Innovations in recombinant and mRNA-based formulations are drawing attention for their enhanced efficacy and faster production cycles. Some regions are adopting tailored immunization strategies that prioritize disease-specific vaccines over broad-spectrum ones. Strategic partnerships between biotech firms and public health agencies are accelerating the development of next-gen alternatives. As cold-chain logistics improve, previously inaccessible vaccines are entering mainstream distribution. Without continuous innovation and differentiation, traditional MMR products risk losing market share to these emerging contenders.

Covid-19 Impact

Lockdowns and healthcare resource reallocation delayed pediatric visits and vaccine administration. However, the crisis also underscored the importance of immunization, prompting renewed investment in vaccine infrastructure. Governments introduced catch-up campaigns and digital tracking systems to recover lost ground. Telehealth platforms and mobile clinics emerged as vital tools for vaccine outreach during restricted mobility. Post-Covid strategies now emphasize resilient supply chains, decentralized delivery models, and integration of MMR vaccines into broader pandemic preparedness frameworks.

The combination vaccines segment is expected to be the largest during the forecast period

The combination vaccines segment is expected to account for the largest market share during the forecast period, due to its convenience and broad-spectrum protection. These formulations reduce the number of injections required, improving compliance among children and caregivers. Technological enhancements in antigen stabilization and adjuvant systems are boosting immunogenicity. Pediatricians prefer combination vaccines for their efficiency in clinical workflows and reduced appointment frequency. Regulatory approvals for newer multi-antigen combinations are expanding the segment's reach. As healthcare systems prioritize integrated immunization schedules, combination vaccines are set to maintain their leadership position.

The pediatric clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatric clinics segment is predicted to witness the highest growth rate. These facilities are increasingly equipped with digital immunization records and automated scheduling systems. Rising birth rates and improved access to primary care are driving footfall in pediatric settings. Clinics are adopting mobile outreach and community engagement models to reach underserved populations. Integration of AI-based diagnostic tools is enhancing early detection and timely vaccination. With growing emphasis on preventive care, pediatric clinics are becoming central nodes in the immunization ecosystem.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by expanding healthcare infrastructure and population density. Countries like India, China, and Indonesia are scaling up national immunization programs with international support. Mobile health units and digital registries are improving vaccine access in remote areas. Regional governments are investing in local manufacturing to reduce dependency on imports. Public-private partnerships are accelerating cold-chain development and last-mile delivery.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological innovation and proactive healthcare policies. The U.S. and Canada are integrating AI and IoT into vaccine distribution and monitoring systems. Regulatory agencies are streamlining approvals for advanced formulations and delivery mechanisms. Telemedicine platforms are expanding vaccine outreach beyond traditional clinics. High public health spending and insurance coverage are supporting widespread adoption. As personalized immunization strategies gain traction, North America continues to set benchmarks for global vaccine deployment.

Key players in the market

Some of the key players profiled in the Measles, Mumps, Rubella (MMR) Vaccines Market include Merck & Co., Inc., Indian Immunologicals Ltd., GlaxoSmithKline plc (GSK), Meiji Seika Pharma Co., Ltd., Sanofi, Panacea Biotec Ltd., Serum Institute of India Pvt. Ltd., LG Chem Ltd., Bharat Biotech International Ltd., Walvax Biotechnology Co., Ltd., Zydus Lifesciences Ltd., Mitsubishi Tanabe Pharma Corporation, Bio-Med Pvt. Ltd., IDT Biologika GmbH, and Sinovac Biotech Ltd.

Key Developments:

In July 2025, Merck and Verona Pharma plc announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

In August 2024, Immunologicals Limited (IIL) has announced partnership with Central Institute of Brackishwater Aquaculture (CIBA), Chennai, an Indian Council of Agricultural Research (ICAR) Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish developed by CIBA.

Products Covered:

  • M-M-R II
  • PRIORIX
  • Tresivac
  • M-M-RvaxPro
  • Other Product Types

Vaccine Types Covered:

  • Standalone Vaccines
  • Combination Vaccines

Route of Administrations Covered:

  • Subcutaneous Injections
  • Intramuscular Injections

Age Groups Covered:

  • Infants (0-1 year)
  • Children (1-12 years)
  • Adolescents
  • Adults

Distribution Channels Covered:

  • Hospital Pharmacies
  • Government Suppliers
  • Retail Pharmacies
  • NGO & International Aid Programs

End Users Covered:

  • Hospitals
  • Public Health Agencies
  • Pediatric Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Product

  • 5.1 Introduction
  • 5.2 M-M-R II
  • 5.3 PRIORIX
  • 5.4 Tresivac
  • 5.5 M-M-RvaxPro
  • 5.6 Other Product Types

6 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Standalone Vaccines
  • 6.3 Combination Vaccines

7 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Subcutaneous Injections
  • 7.3 Intramuscular Injections

8 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Age Group

  • 8.1 Introduction
  • 8.2 Infants (0-1 year)
  • 8.3 Children (1-12 years)
  • 8.4 Adolescents
  • 8.5 Adults

9 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Government Suppliers
  • 9.4 Retail Pharmacies
  • 9.5 NGO & International Aid Programs

10 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Public Health Agencies
  • 10.4 Pediatric Clinics
  • 10.5 Other End Users

11 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Merck & Co., Inc.
  • 13.2 Indian Immunologicals Ltd.
  • 13.3 GlaxoSmithKline plc (GSK)
  • 13.4 Meiji Seika Pharma Co., Ltd.
  • 13.5 Sanofi
  • 13.6 Panacea Biotec Ltd.
  • 13.7 Serum Institute of India Pvt. Ltd.
  • 13.8 LG Chem Ltd.
  • 13.9 Bharat Biotech International Ltd.
  • 13.10 Walvax Biotechnology Co., Ltd.
  • 13.11 Zydus Lifesciences Ltd.
  • 13.12 Mitsubishi Tanabe Pharma Corporation
  • 13.13 Bio-Med Pvt. Ltd.
  • 13.14 IDT Biologika GmbH
  • 13.15 Sinovac Biotech Ltd.

List of Tables

  • Table 1 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By M-M-R II (2024-2032) ($MN)
  • Table 4 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By PRIORIX (2024-2032) ($MN)
  • Table 5 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Tresivac (2024-2032) ($MN)
  • Table 6 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By M-M-RvaxPro (2024-2032) ($MN)
  • Table 7 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 8 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Vaccine Type (2024-2032) ($MN)
  • Table 9 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Standalone Vaccines (2024-2032) ($MN)
  • Table 10 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Combination Vaccines (2024-2032) ($MN)
  • Table 11 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Route of Administration

Table (2024-2032) ($MN)

  • Table 12 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Subcutaneous Injections (2024-2032) ($MN)
  • Table 13 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Intramuscular Injections (2024-2032) ($MN)
  • Table 14 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 15 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Infants (0-1 year) (2024-2032) ($MN)
  • Table 16 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Children (1-12 years) (2024-2032) ($MN)
  • Table 17 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Adolescents (2024-2032) ($MN)
  • Table 18 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Adults (2024-2032) ($MN)
  • Table 19 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 20 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 21 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Government Suppliers (2024-2032) ($MN)
  • Table 22 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 23 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By NGO & International Aid Programs (2024-2032) ($MN)
  • Table 24 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 26 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Public Health Agencies (2024-2032) ($MN)
  • Table 27 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Pediatric Clinics (2024-2032) ($MN)
  • Table 28 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.